IgA Nephropathy: A Disease in Search of a Large-Scale Clinical Trial to Reliably Inform Practice

Giovanni F.M. Strippoli, Ausilia Maione, Francesco P Schena, G Tognoni, Jonathan C. Craig

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Due to its frequency, IgA nephropathy has attracted significant scientific interest. Research has mainly covered the natural history of disease, predictive factors, and pathogenesis. Although IgA nephropathy was first identified as the pathological correlate of “benign recurrent hematuria,” it is now recognized that it is not benign, with about 15% to 40% of patients developing kidney failure within 20 years of kidney biopsy.

Identification of effective treatments for IgA nephropathy has posed challenges for the renal community, and randomized trials like the one described by Lv et al in this issue of the American Journal of Kidney Diseases are welcome additions to a sparse evidence base.
Original languageEnglish
Pages (from-to)5-8
Number of pages4
JournalAmerican Journal of Kidney Diseases
Volume53
Issue number1
DOIs
Publication statusPublished - 2009

Keywords

  • nephropathy
  • effective treatment
  • trials

Fingerprint Dive into the research topics of 'IgA Nephropathy: A Disease in Search of a Large-Scale Clinical Trial to Reliably Inform Practice'. Together they form a unique fingerprint.

  • Cite this